Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

TUG-770

HY-15697

(TUG770; TUG 770)

TUG-770

TUG-770 Chemical Structure

TUG-770 is a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist with EC50 of 6 nM for hFFA1.

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $255 In-stock
5 mg $232 In-stock
10 mg $355 In-stock
50 mg $840 In-stock
100 mg $1400 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO €250 In-stock
5 mg €227 In-stock
10 mg €348 In-stock
50 mg €823 In-stock
100 mg €1372 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: TUG-770
Cat. No.: HY-15697

TUG-770 Data Sheet

  • View current batch:

    Purity: 98.54%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

Related Compound Libraries

Biological Activity of TUG-770

TUG-770 is a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist with EC50 of 6 nM for hFFA1.
IC50 Value: 6 nM (hFFA1, EC50) [1]
Target: GPR40
in vitro: TUG-770 (Compound 22) displayed excellent physicochemical and in vitro ADME properties, with good aqueous solubility, good chemical stability, low lipophilicity, and decreased plasma protein binding (PPB). TUG-770 furthermore showed excellent stability toward human liver microsomes (HLM), no inhibition of selected CYP-enzymes implicated in drug-drug interactions, no P-glycoprotein (P-gp) inhibition, and good permeability in the Caco-2 cell assay [1].
in vivo: Examination of TUG-770 in an acute intraperitoneal glucose tolerance test (IPGTT) in normal mice revealed a good dose dependent response with maximal reduction in glucose level reached at 50 mg/kg.  The effect of TUG-770 was fully sustained after 29 days of daily oral treatment. Additional evaluation of TUG-770 in rats confirmed a significant glucose lowering effect for the high doses already after 10 min and for all doses after 30 min [1].
Clinical trial:
 

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 307.32 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C19H14FNO2
CAS No 1402601-82-4
Solvent & Solubility

10 mM in DMSO

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 3.2539 mL 16.2697 mL 32.5394 mL
5 mM 0.6508 mL 3.2539 mL 6.5079 mL
10 mM 0.3254 mL 1.6270 mL 3.2539 mL

References on TUG-770

Inhibitor Kit

Related GPR40 Products

  • GPR40 Activator 1

    GPR40 Activator 1 is a potent GPR40 activator for treatment of type 2 diabetes.

  • GPR40 Activator 2

    GPR40 Activator 2 is a potent GPR40 activator from patents WO 2012147516 A1, WO 2012046869A1 and WO 2011078371 A1.

  • GW-1100

    GW 1100 is a selective antagonist of GPR40-mediated Ca2(addition) elevations in HEK293 cells stimulated by GW 9508 (an agonist of both GPR40 and GPR120, another GPCR activated by long chain fatty acids) or linoleic acid with a pIC50 value equal to 5.99.

  • GW9508

    GW9508 is a potent and selective agonist for FFA1 (GPR40) with pEC50 of 7.32, 100-fold selective against GPR120, stimulates insulin secretion in a glucose-sensitive manner.

  • TAK-875

    TAK-875 is a potent, selective and orally bioavailable GPR40 agonist with EC50 of 0.072 (mu)M.